APX-115

APX-115 (Ewha-18278) is a potent, orally active pan NADPH oxidase (Nox) inhibitor with Ki values of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 effectively prevents kidney injury[1].

Product Specifications

CAS Number

[1395946-75-4]

Product Name Alternative

Ewha-18278

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

NADPH Oxidase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/apx-115.html

Purity

99.90

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

OC1=C(CCC)C(C2=CC=CC=C2)=NN1C3=NC=CC=C3.Cl

Molecular Formula

C17H18ClN3O

Molecular Weight

315.80

Precautions

H302, H315, H319, H335

References & Citations

[1]Kwon G, et al. A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: possible role of peroxisomal and mitochondrial biogenesis. Oncotarget. 2017 Jun 16;8 (43) :74217-74232.|[2]Cha JJ, et al. APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Lab Invest. 2017 Apr;97 (4) :419-431.